Showing posts with label Cervical Cancer. Show all posts
Showing posts with label Cervical Cancer. Show all posts

Monday, March 18, 2024

2024 SGO Annual Meeting Saturday March 16th Session Review


 

I virtually attended five sessions on day one of the SGO Annual Meeting -  the Opening Ceremony, News We Can All use (Plenary), Moving the Needle (Plenary), Science to Drive Purpose(Plenary)  and Together We Tackle Cancer Rapid Fire Poster Sessions. (Saturday March 16,2024.)

Please be patient while reading this post since it may take some time for all the X posts and photos to download. 

I'm going to start this post by giving a shout out to the patients and advocates involved in presenting on Saturday.  Check out Susan, Linda, Shawn and Jennifer!

Here are just a few of the 60 tweets & retweets I shared during the Saturday meeting.  

Endometrial Cancer

Ovarian Cancer 

HER -2 Expressing Tumors 

Cervical Cancer

Ovarian Cancer 

Endometrial Cancer

Ovarian Cancer

 Recurrent Endometrial, Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer

Endometrial Cancer

Together We Tackle Cancer Session:

I'll keep you updated on what I learned on Sunday and Monday in the next few days.   


Dee 

Every Day is a Blessing!

Posted by at No comments:
Labels: , , , , , , ,

Wednesday, June 7, 2023

ASCO 2023 Day 2: Opening Session, GTD Panel , Gyn Cancer Oral Abstract session

Note: Due to the number of Tweets embedded in this post the page may take some time to load.

Saturday was a busy day at #ASCO23. For me it included live sessions, on-demand sessions and two meetings. 

 Opening Session

 

 

 

The session finished with a chat with the Surgeon General, Dr Vivak Murphy who discussed a range of topics. 


 Case-based Panel - GTD

This session which talked about a Gestational Trophoblastic Disease ( GTD) a rare gyn cancer. I viewed on-demand the day after the presentation. 


Oral Abstract Session

Cervical Cancer - Keynote 826

 

 Ovarian cancer

 Ofranergene obadenove + weekly taxol

GOG 3025 -durvalumab + olaparib + bevacizumab

Luveltamab tazevibulin (STRO-002)


Endometrial Cancer 

 

Did I miss any important gyn studies? Please note them in the comment box. Thanks

Check back tomorrow for highlights from Day 3. 


Dee

Every Day is a Blessing!

Posted by at No comments:
Labels: , , , , , , , , , , ,

Monday, June 5, 2023

ASCO 2023: Day 1- Cervical Cancer, HIPEC, Antibody Drug Conjugates in Gyn Cancers

Note: Due to the number of Tweets embedded in this post the page may take some time to load.

This year I attended #ASCO23 virtually. Some of the sessions were available live but some were on-demand usually a day later. Many of the Tweets I will share in the next few posts were from those I follow who attended those sessions in person. 

Friday, June 2,2023

Clinical Science Symposium  

Cervical Cancer 

An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC):  A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE).       Abtract LBA 5511


 Read more about the above study at https://www.cancer.net/blog/2023-06/asco-annual-meeting-2023-less-extensive-hysterectomy-effective-early-cervical-cancer-and-adding?cmpid=ks_cancernet_net_awareness_sno_facebook_all__glob_060223____aware_photo-text_ 

 

 

 HIPEC in Ovarian Cancer

Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up. (Sonke  abstract 5509) 
Median follow up of 10.1 years. "One hundred and eight patients (87.8%) in the surgery group have died as compared to 100 patients (82.0%) in the surgery-plus-HIPEC group.Median recurrence-free survival was 10.7 months in the surgery group compared to 14.3 months in the surgery-plus-HIPEC group (HR, 0.63; 95% confidence interval [CI], 0.48-0.83; stratified P<0.001). This study provides the first long-term survival analysis of HIPEC in ovarian cancer and confirms the benefit of HIPEC in patients with primary stage III epithelial ovarian cancer undergoing interval cytoreductive surgery. "                                   Overall survival 44.9 with HIPEC versus 33.3 no HIPEC. 
Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: The CHIPOR randomized phase III trial. (abstract 5510)
"The CHIPOR multicentric randomized phase III trial (NCT01376752), conducted in 31 institutions, enrolled patients with a first platinum-sensitive relapse (platinum-free interval of ≥6 months) of EOC. Patients were treated with 6 cycles of platinum and taxane based CT ± bevacizumab, and those amenable to a complete cytoreductive surgery at the end of CT were enrolled and randomly assigned to receive HIPEC (cisplatin 75 mg/m² at 41°C for 60 min) or not. HIPEC significantly improves OS and peritoneal PFS of women with first platinum-sensitive relapse of EOC treated with second-line platinum-based CT followed by secondary complete cytoreductive surgery."
 
 
Education Session 
 Antibody Drug Conjugates: New Opportunities in Gynecologic Cancer

 


 




Dee

Every Day is a Blessing!

Posted by at No comments:
Labels: , , , , , , ,

Wednesday, April 5, 2023

SGO Annual Mtg 2023: Miscellaneous topics

This post completes my coverage of the 2023 SGO Annual Meeting. Below are some tweets on  miscellaneous topics from treatments to testing.

 Cryocompression

Prevention of neuropathy in gyn cancer patients. 

 Immune Biomarkers in Locally Advanced Cervical Cancer 

Combo of durvalumab concurrent with radiation produce more tumor-associated T-cells clones. 

Palliative Care  

Higher value and less aggressive care at end of life with early palliative care.

Palliative care referral was impacted by diagnosis and insurance coverage. 

Breast MRI 

Denials in women with hereditary BRCA1/2 mutations with gyn cancer diagnosis.

Funding gaps  

Significant gaps in funding for gyn cancers compared to other cancer types

Obesity  

Japanese study showed obese women have higher risk of uterine cancer

HPV vaccination

Intervention helps uptake of HPV in clinic 

 Tremelimumab, durvalumab, and radiotherapy

Patients with cervical or vaginal cancers had good overall response rates if high in PDL1

In June I will report on  research of interest presented at the ASCO annual meeting which I will attend virtually. 

Dee

Every Day is a Blessing!

Posted by at No comments:
Labels: , , , , , , , ,

Monday, June 13, 2022

News from #ASCO22 Part 4- Gynecologic Cancer Poster discussion session

This post will cover the Gynecologic Cancer Poster discussion session at #ASCO22 held on Saturday June 5,2022 . I recently watched this on demand.Most of the posters discussed dealt with ovarian cancer.

1)Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study.   5512

 Mirvetuximab soravtansine is an antibody drug conjugate 


MIRV is the first biomarker-directed therapy demonstrating anti-tumor activity in pts with FRα high Platinum-resistant OC.

"MIRV is the first biomarker directed therapy showing anti-tumor activity in patients with Platinum resistant OC". Link to abstract https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.5512#.Yp6b5MzrqnI.twitter

 

 2) Safety and efficacy of MORAb-202 in patients (pts) with platinum-resistant ovarian cancer (PROC): Results from the expansion part of a phase 1 trial. 5513

This study also used an antibody drug conjugate.

"MORAb-202 is an antibody-drug conjugate consisting of farletuzumab (an antibody that binds to folate receptor alpha [FRα]) paired with eribulin mesylate (a microtubule dynamics inhibitor) conjugated via a cathepsin-B–cleavable linker). "

This was a Japanese expansion study and"efficacy was observed irrespective of FRα-expression levels. 

 

slide from distillation presentation -Maroney

3)A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial#10150. 5514

"Anetumab ravtansine (AR) is a fully-human antibody directed at the mesothelin antigen, conjugated to a tubulin polymerization inhibitor". Study was of combination AR/bevacizumab (ARB) versus weekly paclitaxel/bevacizumab (PB). 

 PB had better outcome than weekly ARB leading to the study termination.

Second Group of Posters: Targeted Therapies

 

4) IGNITE: A phase II signal-seeking trial of adavosertib targeting recurrent high-grade, serous ovarian cancer with cyclin E1 overexpression with and without gene amplification. 5515 

Adavosertib is a Wee1 inhibitor 

53%Overall response rate , Clinical benefit 61%, 53% had dose reductions. 
Progression Free survival not yet available.   
 
5) Adavosertib in combination with carboplatin in advanced TP53-mutated platinum-resistant ovarian cancer.   5516
 
38% overall response rate and  76%had dose delays

"Adavosertib 225 mg BID for 2.5 days and carboplatin AUC 5 in a 21-day cycle could be safely combined and shows promising anti-tumor efficacy in patients with platinum resistant ovarian cancer. "
 
6)Efficacy and safety of lucitanib + nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO) 5517
 
"LIO-1 is assessing the oral antiangiogenic, multikinase inhibitor lucitanib in combination with the programmed cell death receptor 1 (PD-1) inhibitor nivolumab"
22% overall response rate and 46% treatment interruptions. 
Third Group of Posters - Maximize remission
7) Real-world effectiveness of first-line maintenance olaparib in women with BRCA-mutated advanced ovarian cancer: U.S. retrospective cohort study. 5518   Real world results follow the SOLO-1 results.  Providers asked to provide information on their patients. 36% of the population were on maintenance only 26% received PARP.                               
Slide from Norquist discussion

 "There was prolonged benefit of 1L olaparib in newly diagnosed pts with BRCAm AOC in terms of lower likelihood of progression."
8 Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study.  5519 

  "In final OS analyses, maintenance olaparib capsules showed consistent clinical activity in BRCAm and sBRCAm PSROC paitents. Exploratory analyses suggest similar activity in non-BRCA HRRm pts."  

9)Role of cytoreductive surgery for the second ovarian cancer relapse in patients previously treated with chemotherapy alone at first relapse: A subanalysis of the DESKTOP III trial. 5520  

"Cytoreductive surgery for subsequent ovarian cancer relapse appears feasible and with low mortality in selected patients who received non-surgical treatment at 1st relapse despite a positive AGO-score." The AGO score is a predictor for which ovarian cancer patients can be operated on with a first recurrence.      

 Rare Gyn Malignancies

10)Basket study of oral progesterone antagonist onapristone extended release (ONA-XR) in progesterone receptor positive (PR+) recurrent granulosa cell (GCT), low-grade serous ovarian (LGSOC), or endometrioid endometrial cancer (EEC)  5521 

ONA-XR is a type I full progesterone antagonist that inhibits progesterone-mediated progesterone receptor activation and stabilizes progesterone receptor association with corepressors. 

 "ONA-XR exhibited a 12-month PFS rate of 20.1% and a CBR of 35.7% in patients with GCT ."                                      

11)A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma.  5522

  

"Neoadjuvant treatment with fulvestrant and abemaciclib was tolerable and demonstrated unprecedented response and CGR rates in this pilot study."

 

12) Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancer.  5523 


 

 

"Our web-based online interactive tool can help with identifying areas with high need of intervention, and inform how access, prevention and new or emerging therapies may potentially change the distribution of r/mCC disease burden"

 

 

 

My last ASCO Annual Meeting post will be the Clinical Science Symposium on Molecular Based Treatment of  Endometrial cancer.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dee

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Every Day is a Blessing! 

 

 

 

 

 

 

 

 

 

             
Posted by at No comments:
Labels: , , , , , , , ,
Subscribe to: Posts (Atom)